Experimental model systems are an indispensable part of research into SCLC. At the International Association for the Study of Lung Cancer’s 2021 Hot Topic Meeting: Small Cell Lung Cancer, keynote […] Read more

A growing body of research in SCLC has revealed greater phenotypic heterogeneity within this disease than previously realized. Circulating-tumor-cell-derived explant models (CDX) are providing researchers with a resource to facilitate […] Read more

Reducing complications after lung cancer surgery could generate positive changes across healthcare, from better outcomes and quality of life to cost savings. Even a small decrease in incidence of postoperative […] Read more

The results of two studies presented at the 2021 World Conference on Lung Cancer—LIBRETTO-321 and ARROW—indicate that the selective RET inhibitors selpercatinib and pralsetinib are promising treatment options for patients […] Read more

Use of platinum-doublet chemotherapy regimen as second-line treatment for patients with relapsed small-cell lung cancer (SCLC) was a reasonable option compared with nonplatinum-based regimens, according to data from a meta-analysis […] Read more

Amid growing interest in validating relapse-prediction models, team links high-grade histology, even if not predominant, with worse outcomes in EGFR-mutated stage 1 NSCLC. Read more

There is a critical need for psychosocial services in the lung cancer care pathway, according to a presentation by Anne-Marie Baird, BS, PhD, on behalf of Lung Cancer Europe (LUCE), […] Read more

Two studies presented at the WCLC Congress 2021 include data that suggest the potential need to update the current TNM classification of lung cancers by implementing additional pathological elements to […] Read more

In 2015, the World Health Organization (WHO) revised its 2004 classification of lung tumors to reflect the impact of genetic, clinical, and radiologic advances in the field.1 Among the revisions […] Read more